WASHINGTON — The Food and Drug Administration and vaccine maker Johnson & Johnson expect to announce as early as Friday that contamination problems at a COVID-19 vaccine plant in Baltimore are resolved, clearing the way for millions more doses to become available.

Vaccine production at the plant run by contract manufacturer Emergent BioSolutions Inc.  EBS, +0.61%  was halted after unsanitary conditions led to contamination of J&J JNJ, -0.15% vaccines. The facility made vaccine substance and finished vaccine doses for J&J and AstraZeneca  AZN, +0.62%  PLC.

Leave a Reply

Your email address will not be published. Required fields are marked *